{
  "id": "52f11b922059c6d71c000004",
  "type": "factoid",
  "question": "Which signalling pathway is involved in Tuberous Sclerosis?",
  "ideal_answer": "Tuberous Sclerosis is a multisystem genetic disorder caused by mutation in TSC1 or TSC2 gene, that leads to hyperactivation of the mTOR signalling pathway, and subsequent dysregulation of cell growth control.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/20457704",
    "http://www.ncbi.nlm.nih.gov/pubmed/19506736",
    "http://www.ncbi.nlm.nih.gov/pubmed/15388940",
    "http://www.ncbi.nlm.nih.gov/pubmed/12766776",
    "http://www.ncbi.nlm.nih.gov/pubmed/12766775",
    "http://www.ncbi.nlm.nih.gov/pubmed/23159330",
    "http://www.ncbi.nlm.nih.gov/pubmed/12556239",
    "http://www.ncbi.nlm.nih.gov/pubmed/12172555",
    "http://www.ncbi.nlm.nih.gov/pubmed/12711473",
    "http://www.ncbi.nlm.nih.gov/pubmed/18368626",
    "http://www.ncbi.nlm.nih.gov/pubmed/15562827"
  ],
  "snippets": [
    {
      "text": "Tuberous Sclerosis Complex (TSC) is a multisystem genetic disorder caused by mutation in either Tsc1 or Tsc2 genes that leads to the hyper activation of the mTOR pathway, a key signalling pathway for synaptic plasticity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23159330",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tuberous sclerosis, caused by germline mutations in the TSC1 or TSC2 genes, is associated with aberrant upregulation of the mammalian target of rapamycin (mTOR) signalling pathway, resulting in growth of tumours, including renal angiomyolipomas (AMLs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20457704",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tuberous Sclerosis Complex is genetically determined with an autosomal dominant inheritance and is caused by inactivating mutations in either the TSC1 or TSC2 genes. TSC1/2 genes play a fundamental role in the regulation of phosphoinositide 3-kinase (PI3K) signalling pathway, inhibiting the mammalian target of rapamycin (mTOR) through activation of the GTPase activity of Rheb.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19506736",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "TSC is an autosomal dominant disorder caused by mutation in either of two genes: TSC1, encoding hamartin, and TSC2, encoding tuberin. Both proteins form a complex inhibiting mTOR signalling pathway and thus regulate cell size and proliferation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18368626",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent findings from this laboratory and others suggests that the tumour suppressor complex made of two proteins TSC1/hamartin and TSC2/tuberin, acts as a negative regulator of mTOR/S6K1 signalling. Mutations in either TSC1 or TSC2 are genetically linked to tuberous sclerosis complex (TSC) syndrome, which can lead to severe pathological consequences, including mental retardation, epilepsy and autism, as well as cardiac, pulmonary and renal failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15562827",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here we review recent findings demonstrating that the TSC1/TSC2 inhibitory complex normally acts on Rheb to mediate mTOR/S6K1-signalling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15562827",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ras homologue enriched in brain (Rheb) represents a unique group of small GTPases and shares moderate sequence identity with the Ras/Rap subfamily. It acts downstream of nutrient signalling as the direct target of the tuberous sclerosis complex (TSC) and upstream of mTOR/S6K1/4EBP in the insulin-signalling pathway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15388940",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent studies suggest that the tuberous sclerosis complex Tsc1-Tsc2 may couple insulin signalling to Tor activity",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12766776",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our genetic and biochemical analyses suggest that Rheb functions downstream of the tumour suppressors Tsc1 (tuberous sclerosis 1)-Tsc2 in the TOR (target of rapamycin) signalling pathway to control growth",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12766775",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our results indicate activation of a mammalian target of rapamycin metabolic pathway in tuberous sclerosis lesions, which contributes to their growth.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12711473",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tuberous sclerosis (TSC) is an autosomal dominant hamartoma syndrome whose causative genes (TSC1 and TSC2) were identified 5 and 9 years ago respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12556239",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent studies in Drosophila have pinpointed a critical function for the DrosophilaTSC1/TSC2 homologues in the regulation of cell size. Epistasis experiments and a variety of biochemical studies that followed have indicated a critical function for these proteins in the highly conserved PI-3-kinase-Akt-mTOR signalling pathway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12556239",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we show that tuberous sclerosis 1 (Tsc1) and Tsc2, tumour suppressors that are responsible for the tuberous sclerosis syndrome, antagonize this amino acid-TOR signalling pathway. We show that Tsc1 and Tsc2 can physically associate with TOR and function upstream of TOR genetically. In Drosophila melanogaster and mammalian cells, loss of Tsc1 and Tsc2 results in a TOR-dependent increase of S6K activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12172555",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.uniprot.org/uniprot/TSC2_RAT",
    "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0033596",
    "http://www.uniprot.org/uniprot/TSC1_RAT",
    "http://www.disease-ontology.org/api/metadata/DOID:13515",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014402",
    "http://www.uniprot.org/uniprot/TSC2_MOUSE",
    "http://www.uniprot.org/uniprot/TSC1_HUMAN",
    "http://www.biosemantics.org/jochem#4266396",
    "http://www.uniprot.org/uniprot/TSC1_MOUSE",
    "http://www.uniprot.org/uniprot/TSC2_HUMAN"
  ],
  "exact_answer": "Tuberous Sclerosis is caused by hyperactivation of the mTOR signalling pathway."
}